Nevro (NYSE:NVRO) announced that it appointed Christofer Christoforou as its new chief operating officer, effective May 15.
Christoforou, 54, initially joined the spinal cord stimulation technology developer in June 2016. He previously served as Nevro’s SVP of technical operations.
Prior to Nevro, he served as VP, quality engineering, at Thoratec, a medical device company. There, he oversaw the operational, design and supplier quality engineering functions.
From October 1999 to December 2014, Christoforou held a number of leadership positions of increasing levels of responsibility at Thoratec. Before that, he spent more than five years in engineering positions at United States Surgical Corporation.
Redwood City, California-based Nevro develops a range of devices, including spinal cord stimulation systems and fixation technology.
The company won FDA clearance for its sacroiliac (SI) joint fusion device without the need to include an accompanying screw in February. It marked the first regulatory nod for the technology since Nevro acquired Vyrsa Technologies and its SI joint pain technologies last year.
Nevro also offers the Senza SCS system for treating painful diabetic neuropathy (PDN). Data presented last year showed that patients receiving this SCS treatment experienced durable pain relief and significant improvements in health-related quality of life (HRQoL) and sleep at 24 months post-implant.
The company, like many others in medtech, announced restructuring efforts this year as well. That included the announcement of a 5% workforce reduction.
